Compare Ecolab Inc. (ECL) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ecolab Inc. vs Sana Biotechnology Inc — how do they compare? Ecolab Inc. trades at $273.22 (market cap $76.06B), while Sana Biotechnology Inc trades at $3.39 (market cap $987.94M). The key difference: Ecolab Inc. is far larger — about 77× Sana Biotechnology Inc's market cap, and Ecolab Inc. pays a 1.08% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| ECL | SANA | |
|---|---|---|
Market Cap | $76.06B | $987.94M |
Sector | Consumer Cyclical | Health |
52-Week High | $308.35 | $5.92 |
52-Week Low | $245.73 | $2.68 |
Enterprise Value | $84.81B | $962.13M |
Dividend Yield | 1.08% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ECL trades at $269.75, down 0.77% on the day, with a bearish technical signal. The stock shows strong fundamentals with 2025 revenue of $16.08B and net income of $2.08B, though recent quarterly EPS results have been mixed. The company recently completed the $4.75B CoolIT acquisition to strengthen its AI cooling portfolio, positioning high-tech as a growth engine. Analyst consensus remains strongly bullish with a $327.43 price target, representing 21% upside potential from current levels.
The outlook is positive given strong analyst support and strategic acquisitions, but risks include execution of the CoolIT integration, rising cost pressures, and mixed quarterly earnings performance. The stock's premium valuation (P/E 36.57) requires sustained earnings growth to justify current levels, making upcoming Q2 2026 results on July 28 critical for near-term direction.
SANA Biotechnology trades at $3.45, down 3.36% today, with a bullish technical signal from moving averages and oscillators. The company shows strong analyst support with 82% buy ratings but faces significant financial challenges including negative ROE of -147.41% and consistent quarterly losses. Recent developments include positive clinical data presentations and a strategic collaboration with Mayo Clinic announced in May 2026.
While technical indicators suggest near-term upside potential and analyst sentiment remains positive, fundamental weaknesses including substantial cash burn and negative profitability present significant investment risks. The stock's outlook depends heavily on successful clinical development and future revenue generation from its engineered cell therapies.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ecolab Inc.
Ecolab produces and markets cleaning and sanitation products for the hospitality, healthcare, and industrial markets. The firm is the global market share leader in this category with a wide array of products and services, including dish and laundry washing systems, pest control, and infection control products. The company has a strong hold on the U.S. market and is looking to increase its profitability abroad. Additionally, Ecolab serves customers in water, manufacturing, and life sciences end markets, selling customized solutions.
Read more on ECL →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
